Author:
Hall G D,Brown J M,Coleman R E,Stead M,Metcalf K S,Peel K R,Poole C,Crawford M,Hancock B,Selby P J,Perren T J
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD (1985) Intraperitoneal recombinant alpha-interferon for ‘salvage’ immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Cancer Res 45: 4447–4453
2. Berek JS, Markman M, Stonebraker B, Lentz SS, Adelson MD, DeGeest K, Moore D (1999) Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study. Gynecol Oncol 75: 10–14
3. Bruzzone M, Rubagotti A, Gadducci A, Catsafados E, Foglia G, Brunetti I, Giannessi PG, Carnino F, Iskra L, Rosso R, Martoni A, Pannuti F, De LV, Maltoni R, Ridolfi R, Mammoliti S, Gallo L, Boccardo F, Ragni N, Conte PF (1997) Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. Gynecol Oncol 65: 499–505
4. Einhorn N, Ling P, Einhorn S, Strander H (1988) A phase II study on escalating interferon doses in advanced ovarian carcinoma. Am J Clin Oncol 11: 3–6
5. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Blumenson LE (1998) Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 71: 190–195
Cited by
79 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献